ArticleImmunology2000
Regulation of epidermal Langerhans cell migration by lactoferrin.
Article in Immunology, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 79 citations in OpenAlex.
- IL-1beta-induced Langerhans' cell migration and TNF-alpha production in human skin: regulation by lactoferrin.Clinical and experimental immunology · 2003Trial
- Review
- Multifunctional iron bound lactoferrin and nanomedicinal approaches to enhance its bioactive functions.Molecules (Basel, Switzerland) · 2015Review
- Skin sensitization induced Langerhans' cell mobilization: variable requirements for tumour necrosis factor-α.Immunology · 2015Article
- Inhibitory effects of human lactoferrin on U14 cervical carcinoma through upregulation of the immune response.Oncology letters · 2014Article
- Towards scarless wound healing: a comparison of protein expression between human, adult and foetal fibroblasts.BioMed research international · 2014Article
- Antimicrobial peptides: old molecules with new ideas.The Journal of investigative dermatology · 2012Review
- Protecting the boundary: the sentinel role of host defense peptides in the skin.Cellular and molecular life sciences : CMLS · 2011Review
- Lactoferrin modulation of BCG-infected dendritic cell functions.International immunology · 2009Article
- Lactoferrin as a natural immune modulator.Current pharmaceutical design · 2009Review
- Antimicrobial peptides and the skin immune defense system.The Journal of allergy and clinical immunology · 2008Review
- Lactoferrin acts as an alarmin to promote the recruitment and activation of APCs and antigen-specific immune responses.Journal of immunology (Baltimore, Md. : 1950) · 2008Article
- Oral lactoferrin results in T cell-dependent tumor inhibition of head and neck squamous cell carcinoma in vivo.Clinical cancer research : an official journal of the American Association for Cancer Research · 2007Article
- Role of the parasite-derived prostaglandin D2 in the inhibition of epidermal Langerhans cell migration during schistosomiasis infection.The Journal of experimental medicine · 2001Article
- Antimicrobial peptides in human skin disease.European journal of dermatology : EJDReview
- Expression of three intelectins in sheep and response to a Th2 environment.Veterinary researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lactoferrin (LF) is a member of the transferrin family of iron-binding glycoproteins to which several anti-inflammatory functions have been ascribed. LF has been shown to down-regulate expression of the pro-inflammatory cytokine tumour necrosis factor-alpha (TNF-alpha), although the possibility has been raised that the activity of LF in this regard was indirect and secondary to its ability to bind to and inactivate the bacterial lipopolysaccharide (LPS) used to induce cytokine production. However, the identification of putative membrane receptors for LF raises the possibility that the interaction of LF with its receptor may be one important route through which this protein exerts anti-inflammatory activity. In the present investigations the biological properties of LF have been examined in a model of cutaneous immune function where the allergen-induced migration of epidermal Langerhans cells (LC) from the skin and their subsequent accumulation as dendritic cells (DC) in skin-draining lymph nodes are known to be dependent upon the de novo synthesis of TNF-alpha, but independent of exogenous LPS. Consistent with the protein having direct anti-inflammatory properties, it was found that the intradermal injection of recombinant murine LF (either iron-saturated or iron-depleted LF) inhibited significantly allergen (oxazolone) -induced LC migration and DC accumulation. That these inhibitory effects were secondary to the inhibition of local TNF-alpha synthesis was suggested by the findings that first, LF was unable to inhibit LC migration induced by intradermal injection of TNF-alpha itself, and second, that migration stimulated by local administration of another epidermal cytokine, interleukin 1beta, which is also dependent upon TNF-alpha production, was impaired significantly by prior treatment with LF. Finally, immunohistochemical analyses demonstrated the presence of LF in skin, associated primarily with keratinocytes. Collectively these data support the possession by LF of direct immunomodulatory and/or anti-inflammatory activity, probably associated in this case with inhibition of cytokine production. Furthermore, the results suggest that as a constituent of normal skin, LF may play a role in homeostatic regulation of cutaneous immune function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.